-
Innovating for Hope of Better Health,
Beyond Child Growth
We are patient-centered, addressing the unmet medical needs in five therapeutic fields...
-
Women's healthAt the core of our services is Assisted Reproductive Technology (ART). We specialize in infertility, common gynecological conditions, menopausal health, and beauty and body management, offering a comprehensive range of products tailored to the health needs of women throughout their lives
-
Gouty arthritisPioneering long-acting, targeted therapies for gout in China
RESEARCH AND DEVELOPMENT
Sustaining Innovation...
-
70+
Marketed Products(*pharmaceuticals, diagnostic devices, and medical nutrition products, etc. )
-
20+
Clinical Pipeline
-
22%
R&D investment as a percentage of sales revenue in 2024
To challenge, to create, to push the boundaries of what is possible...
Latest News
-
2025-12-02
A Leading Force in Innovation:
GenSci Earns Dual Recognition as Global Innovator & 2025 China Pharma Top 100Learn More
-
2025-10-24
GenSci Invites You to Meet Us at CPHI FRANKFURT 2025Learn More
-
2025-10-24
GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMSLearn More
-
2025-10-13
GenSci Advances Women's Health with the Approval of Two Key ProductsLearn More
-
2025-10-09
From Long-acting Growth Hormone to Medical Devices: GenPEG Advances its High-purity ExpertiseLearn More
-
2025-09-18
GenSci Partners with Allergy Immunotherapy Leader ALK to Bring Innovative AIT Solutions for Chinese PatientsLearn More
-
2025-07-14
First Prescription for Firsekibart Issued in China for GALearn More
-
2025-07-04
Firsekibart Approved with 87% Reduction in Gout Recurrence Over 6 MonthsLearn More
-
2025-06-18
Gensci Showcases Women's Health and Immunology Innovations at BIO 2025Learn More
-
2025-06-18
NMPA Approves New Indication Clinical Trial of Megestrol Acetate Oral SuspensionLearn More
-
2025-06-17
Gensci Showcases BsADC Pipeline at 4th World ADC Asia SummitLearn More
-
2025-05-30
The FDA has Cleared the IND Application for GenSci128 for TP53 Y220C-Mutated Solid TumorsLearn More
-
2025-05-20
GenSci 2025 R&D Day: The Next Growth Frontier for a Billion-Dollar Growth Hormone LeaderLearn More
-
2025-03-21
Global R&D Milestone: Clinical Trial of GenSci120 Will Be Launched in the U.S.Learn More
-
2025-03-07
Episil® Launched in China: A Breakthrough Solution for Oral MucositisLearn More
-
2025-02-20
GenSci Submits Another Blockbuster Product for Market ApprovalLearn More
-
2024-11-20
Chinese Monoclonal Anti-IL-1β Breakthrough: Acute Gout Arthritis Treatment Impresses at ACR 2024Learn More
-
2024-11-11
World ADC San Diego 2024: GenSci showcases two innovative pipeline programsLearn More
-
2024-11-07
Welcome to Visit Us at MEDICA 2024Learn More
-
2024-10-25
GenSci' s Inaugural R&D Day 2024: Innovation in Gene, Science in Actionsuccessfully concluded on October 17, 2024
Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More
-
2024-06-28
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® ApprovedA further step towards GenSci's vision of becoming a global leader in Pediatric and Women's Health
Learn More
-
2024-06-19
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia®Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia® in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.
Learn More
-
2024-06-05
Visit GenSci at CPhI China 2024At Booth W4E59, See you there!
Learn More
-
2024-05-26
NMPA Approves Genakumab Injection for Clinical Trial Commencementwhich marks the initiation of bioequivalence studies for the new formulation of Genakumab Injection
Learn More
-
2024-05-17
Jintrolong® PEG-rhGH from GenSci highlighted at ECE 2024Jintrolong® PEG-SOMATROPIN was highlighted during the Growth Hormone Research Society (GRS) symposium at the largest endocrine event in Europe
Learn More
-
2024-04-11
R&D Progress: NMPA Approves Genakumab to the MarketMajor R&D Progress
Learn More
-
2023-12-22
GenSci Launches Global Innovation Hub in ShanghaiThe Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges
Learn More